NexMed Appoints Dr. Stephen B. Howell, World Renowned Key Opinion Leader In Oncology As Chairman Of Its Scientific Advisory Board
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of products based on the NexACT ® technology, today announced the appointment of Stephen B. Howell, M.D., as Chairman of its Scientific Advisory Board.
Commenting on today’s news, Dr. Bassam Damaj, Chief Executive Officer of NexMed, noted, “We are very pleased to welcome Steve as Chairman of our Scientific Advisory Board. He is recognized as a world-class, key opinion leader in oncology and his expertise will be especially valuable as we continue the development of our cancer therapies.”
Dr. Howell currently serves as a medical oncologist and Professor of Medicine at the University of California, San Diego. He also serves as Associate Director for Clinical Research and Director of the Cancer Therapeutics Training Program at the Moores Comprehensive Cancer Center at the University of California, San Diego, and runs the Clayton Foundation Drug Resistance Laboratory at the Cancer Center. During his career, Dr. Howell has co-founded three pharmaceutical companies, including DepoTech (1989), Beacon Laboratories (1995), and Targa Pharmaceuticals (2003), serving as Medical Director of each.
Dr. Howell holds a number of patents for his innovative work in chemotherapeutics, drug-delivery systems, and diagnostic assays and is the recipient of numerous awards, including the Milken Family Medical Foundation Award for Outstanding Work in the Field of Cancer Research, a presidential citation from the American Head and Neck Society, and a Fogarty Senior International Fellowship. He is currently one of the main organizers of the American Association of Cancer Research.Dr. Howell is a graduate of Harvard Medical School and is board certified in internal medicine and medical oncology. He completed his internship, residency, and medical oncology training at the Massachusetts General Hospital, the University of California, San Francisco, and the Dana Farber Cancer Institute, respectively. He completed his research training at the National Institutes of Health.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV